Modulators of cell adhesion, methods and compositions therefor
Compounds with activity as modulators of cell adhesion are disclosed. The compounds are derivatives of piperidin-4-amine. In some embodiments, a compound can be linked to a targeting agent, a pharmaceutically active substance and/or a support material. Methods for enhancing or inhibiting classical cadherin-mediated functions are also disclosed. The compounds can be used for the treatment or prevention of a variety of diseases including cancer. Compositions and devices, including skin patches comprising a compound are also disclosed. In addition, methods of synthesis of the compounds are provided.
1. A method of treating a fibrotic disease in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount (S)-1-(3,4-dichlorophenoxy)-3-(4-(((S)-2-hydroxy-3-(4-methoxyphenoxy)propyl)amino)piperidin-1-yl)propan-2-ol
or a pharmaceutically acceptable salt thereof.
2. A method in accordance with claim 1 , wherein the fibrotic disease is selected from the group consisting of fibrosis, restenosis, sclerosis and rheumatoid arthritis.
3. A method in accordance with claim 1 , wherein the fibrotic disease is rheumatoid arthritis.
4. A method in accordance with claim 1 , wherein the fibrotic disease is restenosis.
5. A method in accordance with claim 1 , wherein the fibrotic disease is fibrosis.
6. A method in accordance with claim 1 , wherein the fibrotic disease is a cancer.
7. A method in accordance with claim 6 , wherein the cancer is selected from the group consisting of pancreatic cancer, prostate cancer, multiple myeloma, chronic myelogenous leukemia, melanoma and neuroblastoma.
8. A method in accordance with claim 5 , wherein the fibrosis is pulmonary fibrosis.
9. A method in accordance with claim 5 , wherein the fibrosis is idiopathic pulmonary fibrosis.
10. A method in accordance with claim 5 , wherein the fibrosis is liver fibrosis.
11. A method in accordance with claim 5 , wherein the fibrosis is kidney fibrosis.
12. A method in accordance with claim 1 , wherein the fibrotic disease is multiple myeloma.
13. A method in accordance with claim 1 , wherein the fibrotic disease is arteriosclerosis.
14. A method in accordance with claim 1 , wherein the fibrotic disease is cutaneous lymphoma.
15. A method in accordance with claim 1 , wherein the fibrotic disease is keloids.
16. A method in accordance with claim 1 , wherein the fibrotic disease is scarring.